Nama's AI scorecard currently rates IRADIMED Buy (8.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is IRMD's P/E ratio?

IRADIMED trades at a trailing price-to-earnings ratio of 42.3.

When does IRMD report earnings?

IRADIMED's next scheduled report is on Feb 10, 2027. Analysts expect EPS of $0.60.

What is the IRMD price target?

The median analyst price target from 2 analysts is $118.00, with a range of $116.00 – $120.00.

Is IRMD Shariah compliant?

Nama's AAOIFI-style screen reads IRADIMED as Can't Tell. A figure the screen needs is missing, so it can't tell.

Does IRMD pay a dividend?

Yes — IRADIMED's dividend yield is 0.9%.

Nama Insights

IRADIMED (IRMD)

Healthcare · Medical Devices · NASDAQ

IRADIMED (IRMD) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $1.10B, a trailing price-to-earnings ratio of 42.3 and a free-cash-flow yield of 1.5%. Over the most recent reported fiscal year, revenue grew 14.4% and free cash flow per share fell 2.2%. Nama's AI scorecard rates it Buy, 8.2 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Buy · 8.2/10

Clearly positive, short of the top band. As of Nov 7, 2026.

Momentum

Middle · +1.0% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Can't Tell

A figure the screen needs is missing, so it can't tell.

Off its high

-20.0%

How far the last close sits under the highest price of the past five years.

Market cap	$1.10B
Trailing P/E	42.3
Price / book	10.8
Price / sales	12.3
FCF yield	1.5%
Dividend yield	0.9%
Gross margin	75.9%
Operating margin	31.9%
Net margin	26.7%
Revenue growth (YoY)	+14.4%
Revenue growth (3-yr annual)	+16.3%
EPS growth (YoY)	+19.2%
FCF/share growth (YoY)	-2.2%
Beta	0.9
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Devices

IRMD earnings

Next report: Feb 10, 2027 (Q4 2026, EPS estimate $0.60). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 30, 2026	$0.55	$0.55	+0.0%	$24.20M
Q2 2026	Jul 31, 2026	$0.46	$0.44	+4.5%	$20.47M
Q1 2026	May 1, 2026	$0.49	$0.45	+8.9%	$21.98M
Q4 2025	Feb 10, 2026	$0.54	$0.48	+12.5%	$22.69M

IRMD analyst price target

Median target $118.00 from 2 analysts, ranging $116.00 – $120.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live IRMD data on Nama Insights →

IRMD FAQ

Is IRMD a buy?: Nama's AI scorecard currently rates IRADIMED Buy (8.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is IRMD's P/E ratio?: IRADIMED trades at a trailing price-to-earnings ratio of 42.3.
When does IRMD report earnings?: IRADIMED's next scheduled report is on Feb 10, 2027. Analysts expect EPS of $0.60.
What is the IRMD price target?: The median analyst price target from 2 analysts is $118.00, with a range of $116.00 – $120.00.
Is IRMD Shariah compliant?: Nama's AAOIFI-style screen reads IRADIMED as Can't Tell. A figure the screen needs is missing, so it can't tell.
Does IRMD pay a dividend?: Yes — IRADIMED's dividend yield is 0.9%.